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Graft survival after renal transplantation: Agenda for analysis
SHEILA M. GORE
Medical Research Council Biostatistics Unit, Medical Research Council Centre, Cambridge, United Kingdom
The use of more sophisticated statistical techniques in the
analysis of graft survival is indicated on two accounts. Firstly,
in the United Kingdom the mysterious, wide variation in graft
and patient survival rates across different renal units masquer-
ades still under the sobriquet of the "center effect." Also, there
has been steady improvement over the years in graft survival,
but the reasons for this have not been established in simple
lifetable analyses. Recent advances in the statistical modeling
of survival [1—4] mean that there is now sufficient flexibility in
available methods to begin to unravel the complexity of graft
survival. This complexity is perhaps best illustrated by 3-year
graft survival rates ranging from 20 to 80% in United Kingdom
transplant units when analyzed in 1981.
The careful collection of information on the treatment of
patients with renal failure has been a valuable contribution of
the European Dialysis and Transplant Association (EDTA), and
other organizations around the world have similar data-bases,
as do individual units. Now is the time for taking stock.
Detailed exploration of the data relating to graft survival can
lead to inferences about the natural history of disease, as well as
identifying treatments which need to be evaluated in random-
ized clinical trials. The first essential is that there be a plan of
how to explore survival data. Such a plan is outlined in the
following sections. It entails organizing and checking survival
and covariate data, providing a general description of the
transplant series so that the reader is aware of interdependence
among covariates, and plotting lifetables and the time-specific
risk of graft failure. The limitations of analyzing one prognostic
factor at a time are illustrated with examples in one section.
These show the need for a multifactorial approach so that
regression models for survival are introduced in a subsequent
section. The relevance of covariates may be time-dependent, a
possibility which is explored. In another section, the "center
effect" on graft survival is discussed. One consideration is that
discrepancies in graft survival between centers may be ex-
plained in terms of patients' pretransplant rehabilitation for
which a scoring system would be useful. In the last section the
case for randomized clinical trials in renal units is presented and
a survey of research priorities is suggested. Factorial designs
are emphasized.
Organizing survival data and data quality
How to organize and check survival data for patients who
have received a renal graft is described in Table 1. Of course,
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graft survival time is not all that is known of such patients.
Associated with each recipient are covariates (see below) which
possibly influence graft survival. Thus, the computer record for
a given patient might detail age, the duration of pretransplant
dialysis, the number of transfusions given, donor age, warm
ischemic time, a local versus an imported kidney, sensitization,
histocompatibility, immunosuppression regime, and so forth. I
shall use the name covariates to describe these additional
factors. Before analysis, covariate data as well as survival data
need to be checked for sensible range, correct arithmetic, and
coherence. Errors which are not implausible will go undetected,
but the extent and seriousness of residual errors can be estimat-
ed by comparing a random sample of the computer-held records
with the original case histories. Even this will not uncover
errors which are inherent in the notes.
Reliability is emphasized because plainly no amount of
analysis can compensate if the data are poor.
A general description
A general description of the data is obligatory if one is to
avoid errors in interpretation. In particular, the pattern of
referral annually and distribution of patients by covariates need
to be detailed. Thus, when results from a particular renal unit
are considered, the reader would expect to see the age distribu-
tion of recipients, the distribution of HLA-A and HLA-B
matches compared for local and imported kidneys, a scatter-
gram of duration of pretransplant dialysis against age of the
recipient, and the distribution of cold ischemic time. Additional
relevant information should include the number of trans-
plants performed per year per million of population, the propor-
tion of sensitized patients among those transplanted, the pro-
portion of recipients who have multisystem disease, the policy
on the number of transfusions and immunosuppression, and an
indication of how these policies are interpreted in practice, for
example, by an analysis of transfusions received. Analysis of
two-way and multiway contingency tables should lead to gener-
al inferences about the type of patient who was selected for
transplantation. The reader is alerted to associations between
covariates, such as the mean number of HLA-A and -B matches
being higher in imported than in local kidneys [5], which may
have implications for the analysis of graft survival. This point is
discussed in the section on multifactorial methods.
It is against this background of disease presentation that
survival analysis is introduced. A large number of publications
have failed in the past to provide information on all, or even
some of, these covariates.
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Table 1. Organizing graft survival data
Having determined the point of analysis (for example, December 31,
1982), the first step is to update the follow-up on all patients so that each
case history is summarized by only one of three descriptions. For graft
survival the three descriptions are:
A The patient died with a functioning graft, or the graft was rejected
on . . . (give the date). Notice that if inferences about competing
risks for death or rejection are to be made, then the cause of failure
(death/rejection) should be noted.
B The patient is known tobe alive with a functioning graft at the time
of analysis (supposition is not good enough).
C The latest date before analysis on which the patient was known to
be alive with a functioning graft is . . . (give the date and note the
reason for information being incomplete).
The next step is to check that the sequence of dates is correct for a
given patient; any inversion, such as the date of rejection preceding the
date of transplantation, suggests a transcription error. Now convert the
dates into survival time in days, checking arithmetic. Survival time is
exact for patients whose graft has been rejected or who have died, and
is right-censored for patients who satisfy descriptions B and C; these
patients would have survived with a functioning graft for a time of at
least so many days. The information is now in a form that makes it
straightforward to compute lifetables [3].
Ljfetables, covariates, and time-specific risk of graft failure
The calculation of a lifetable for graft survival depends on a
simple recurrence. Beginning with time t =0, the probability of
the graft surviving for (t + 1) days after transplantation equals
the probability of its surviving for t days, multiplied by the
probability of neither rejection nor death on the next day. The
last term, the probability of escaping failure on day (t + 1), is
reached by counting (1) how many grafts are at risk on day (t +
1): only those patients whose recorded graft survival time is (t +
1) days or more are in the group at risk; (2) how many fail on
day (t + 1) by reason of rejection or death; and then computing
the probability of surviving that day as one minus the propor-
tion of grafts which failed. The lifetable is a step function which
estimates true graft survival unbiasedly; the steps occur only at
times of rejection or death. A worked example together with
further explanation is given in an expository paper by Peto et al
[3].
Historically 3-month, 6-month, and N-year graft survival
rates have been the basis for informal comparison of renal units.
Tabular presentation (ranked) of these data is a convenient
summary but telescoping the lifetable (Fig. 1) entails loss of
information, particularly about the pattern of death and rejec-
tion during the important first 3 months after transplantation. In
the 1981 Annual Report of the United Kingdom Transplant
Service, the logrank test [3] was introduced formally to com-
pare graft survival in the first 3 months thus making efficient use
of the data from each renal unit. The value of the lifetable is of
course that it shows for any time tin the range of the data what
is the estimated probability of the graft surviving for t days or
more.
It is not only the lifetable for the series as a whole which
interests us when exploring survival data. Graphical methods
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have a part to play in the initial study of prognostic factors. By
plotting the graft survival of patients in a particular renal unit
who have zero HLA-A and -B matches and comparing with the
lifetables for patients who have one and two or more matches,
respectively, we can make a preliminary assessment about
histocompatibility as a predictor of graft survival. At this stage,
significance testing has value only in so far as it ensures that we
do not over-react to small differences in graft survival that are
explicable by chance variation.
An important question remains. How does the risk of graft
failure change with elapsed time since transplantation? The
pattern of graft failure is not immediate from the lifetable, which
cumulates information over time. It is not easily discerned in
small series, for unless investigators can study intervals of
follow-up covering a sufficient number of graft failures estima-
tion will be unreliable. Although there may be a loss of detail, it
is still worthwhile to have an overview of the pattern of graft
failure.
Table 2 summarizes the lifetable for 200 cadaveric grafts
which were transplanted at center A (hypothetical) between
January 1978 and December 1980 and also for the 300 cadaveric
grafts which were transplanted at that center in the 5 years up to
December 1977. Although hypothetical, these data are selected
to reflect United Kingdom transplant experience in these years.
In the 1978 to 1980 series, 7% of grafts failed within 60 days of
transplantation; of the 60-day survivors the proportion with a
functioning graft at 120 days is estimated from the lifetable as
88/93 so that the risk of graft failure in the second 60-day
interval is 5%. From 120 days to 360 days, the risk of graft
failure is estimated over 120-day periods and is not directly
comparable with the preceding estimates, except after adjust-
ment; division by two is considered a good enough approxima-
tion here. The percentage of grafts which failed between 120
and 240 days after transplantation was 6% and fell to 2% in the
follow-up period from 240 to 360 days.
For the series as a whole, the risk of graft failure thus seems
to decrease with time elapsed since transplantation. There are
two reasons why this finding should not be overinterpreted. The
first is that the pattern of graft failure in important subgroups,
that is, patients with zero, one and two or more HLA matches,
might be different altogether from the overall picture and needs
to be looked at specifically. For another illness, breast cancer, a
series of patients was studied at the Western General Hospital
in Edinburgh [6]. The annual proportion dying decreased for the
100
80
60>>
(0
I I I I I I I
' 20 40 60 80 120 180 240 300 360
Time from transplantation, days
Fig. 1. Loss of detail when lifetable for graft survival is telescoped.
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Table 2. Time-specific risk of graft failure (hypothetical data)
1978 to 1980 series 1973 to 1977 series
Days after At Percent At Percent Graft failure
transplantation risk surviving Graft failure ratea risk surviving ratea
0 200 100 300 100
60 186 93 7% 240 80 20%
120 176 88 100 x (8) = 5% 204 68 15%
240 166 83 100 x (3) = 6% 186 62 9%
360 162 81 100 x (f.) = 2% 180 60 3%
720 105 75 100 (.5) = 165 55 8%
a The risks of graft failure are given for intervals of length 60, 60, 120, 120, and 360 days. Nine percent of grafts failing in a period of 120 days
means that the 60-day failure rate is of the order of 5%.
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series as a whole (Fig. 2), but in each of stage 1, 2, and 3 disease
the pattern is of increasing mortality in the first few years after
the diagnosis and followed by a slow decline (Fig. 3). The
second comment is that there could be systematic fluctuations
in the risk of graft failure at certain times, for example,
according to some biological rhythm, which cannot be detected
except in a much larger series than is being considered.
The graft failure rates given in Table 2 are of course esti-
mates, which have standard errors associated with them. The
estimates of 5 and 15% failure in the two series in the interval
from 60 to 120 days, respectively, have approximate standard
errors [3]
95 x = 1.6% and 85 x = 2.3%
so that a 95% confidence interval for the difference in time-
specific failure rates is achieved by computing —10 1.96 x
Vl.62 + 2.32. This confidence interval, from —15.5 to
—4.5%,
strongly suggests that the reduction in failure rate is real. In the
interval from 120 to 240 days after transplantation, the risks of
graft failure are not significantly different between the series,
the 95% confidence interval for the true difference being from
—8.3 to 2.3%, which embrances zero.
Notice that the improved prospect for graft survival in the
Fig. 3. Mortality year by year: international stage (Reprinted with
permission from [61).
immediate post-transplant period for patients who received a
transplant in the years 1978 to 1980 could be explained by a
variety of factors: patient selection, better surgical technique,
more effective immunosuppression regime, improved patient
monitoring after transplantation, and so forth. A multifactorial
approach is needed to identify the relevant factors. An investi-
gator would also want to verify the observation that in the later
follow-up periods the risks of graft failure had not significantly
improved, with the implication that the advantage was in some
aspect of selection or management having its effect only in the
period up to 120 days.
The need for a multifactorial approach
Simple summaries, tables, scattergrams, and illustrations of
graft survival and time-specific failure rate can be used to good
effect. These give a general description of the data and an initial
impression of which covariates may be related to graft survival.
The next step is to group together those prognostic factors
which, from the general description of the data, are known to be
highly correlated or interdependent. The reason for focusing
attention on these sets of covariates is to create an awareness of
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at risk 3918 2763 1845 1166 642 238
Fig. 2. Mortality year by year: Western General breast cancer series (N
= 3918) [71.
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Table 3. Description of 145 kidneys grafted at Center B (hypothetical)
Number of
HLA matches Local Imported Totals
0 20 5 25
1 35 10 452 35 40 75
Totals 90 55
the possible distortions that analyzing survival one variable at a
time can introduce. Examples of these distortions are: (1) one
or more covariates carrying prognostic information about graft
survival not in its own right, but only through association with
other covariates in the set; (2) the effect of a particular
prognostic factor being underestimated, exaggerated or even
reversed because of its interdependence on others; (3) two (or
more) covariates carrying essentially the same prognostic infor-
mation, knowledge of either one serving as well for predicting
graft survival as do both, The two covariates are then "proxy"
variables, the one for the other; (4) interaction in respect of
graft survival between two covariates, their joint effect being
more (or less) devastating than is predicted by their separate
effects. The above complexities can be best illustrated by an
example. Recall that the dichotomy: the local versus the
"imported" kidney and the covariate: Number of HLA-A and
-B matches are interdependent, because HLA matching is
better, on the average, for imported rather than for local
kidneys. Table 3 gives the description of 145 kidneys which
were grafted at center B (hypothetical) from January 1978 to
December 1980. Three models of what the relationship might be
between the two covariates and graft survival at 3 months are
given, in turn, in Tables 4, 5, and 6 and are translated into the
number of grafts that would be expected to survive up to 3
months. Analyzing survival by one covariate at a time fails to
identify these relationships correctly. The frequency distribu-
tion in Table 3 is typical of many United Kingdom transplant
centers. The distortions illustrated will occur when considering
real data, unless analysis of graft survival goes beyond univar-
iate methods.
In the first model (Table 4) the two covariates have separate
effects. The probability of graft survival at 3 months increases
with the number of H LA-A and -B matches, and irrespective of
HLA matching, the survival rate for imported kidneys is 80% of
that for local kidneys. The single-covariate summary tells us
that 73.5 local grafts are expected to survive to 3 months, giving
a 3-month survival rate of 73 .5/90 or 82%. The corresponding
survival rate for imported grafts is 69%. The ratio of these two,
69/82, is 0.84, which underestimates (Distortion B) the real
handicap (0.80) associated with imported kidneys. Similarly,
the advantage of having two or more HLA-A and -B matches is
understated (compare the ratios 0.9/0.8 = 1.125 and 0.80/0.76 =
1.05) if only this variable is observed.
In Table 5 we assume no effect on graft survival of the
dichotomy: the local versus the imported kidney. As in Table 4
the probability of graft survival at 3 months increases with the
number of HLA-A and -B matches. The single-covariate analy-
sis misleadingly suggests a difference in 3-month graft survival
rates between local and imported kidneys (Distortion A). The
apparent advantage (86% survival for imported kidneys com-
pared with 82% for local kidneys) derives from the different
distribution of HLA-A and -B matches according to the source.
It is not specific to the dichotomy: local versus imported
kidney. For confirmation, look at the effect of source within
each level of HLA-A and -B matching and pool the three
estimates; the answer is zero effect throughout.
One could remark in passing that the kidney source may be a
proxy variable for cold ischemic time (Distortion C).
In the third model (Table 6) interaction, in respect of graft
survival, is postulated between the effects of the two covar-
iates. The probability of graft survival at 3 months increases
with the number of HLA-A and -B matches, and the survival
rate is less for the imported than for the local kidneys, but the
penalty of having an imported kidney is far greater if there is no
matching (50% reduction in 3-month survival) than if there are
two or more HLA-A and -B matches. Analysis of one covariate
at a time cannot reveal interactions between determinants for
survival (Distortion D). Nor will they be discovered in the
statistical modeling of survival data unless interaction terms are
fitted as well as separate covariate effects. The purpose of
fitting interaction terms in a regression model is to pick up
patterns such as in Table 6, in which the effect of one covariate
(the source of the kidney: local or imported) is more pro-
nounced at some levels of HLA matching than at others.
In practice random variation is superimposed on the results in
Tables 4 to 6. Statistical methods are needed to infer the
structure from which observational data come. What is usually
wanted is as simple a structure as is consistent with the
observations with only interactions which are highly significant
(P < 0.01), or for which there is prior evidence, being retained.
This is, in part, to avoid the dangers inherent in multiple
significance tests: Covariates give rise to ten first order interac-
tions and in general for p covariates there are p(p— l)/2 for first-
order interactions. In testing all of these individually the chance
of false positives becomes unacceptably high unless the test
criterion is sufficiently strict. One such strict criterion
which preserves the overall type 1 error is a global test of
interaction. The explanatory value of a group of interactions is
assessed by a x2 statistic having degrees of freedom equal to the
number of interactions tested.
The statistical modeling of survival data is discussed in more
detail in the following section.
Statistical modeling of graft survival
The limitations of single variable comparisons of graft surviv-
al have been demonstrated. Statistical methods which allow one
simultaneously to test the significance of several prognostic
factors and estimate their importance, that is, regression mod-
els for survival, are now considered. Four statistical models for
survival [4] are presented in terms of the time-specific risks of
graft failure which they entail.
The first of these is characterized by constant hazard and is
called the exponential model. It would mean that no matter
what the elapsed time since transplantation was the risk of graft
failure would stay the same. There is then the Weibull model
with monotone risk of graft failure. If monotone decreases, the
risk of graft failure falls steadily as ' where t is time after
transplantation and c is a positive value less than one. The
proportional hazards model [1, 2] comes next. It is a more
general and rather elegant framework for analyzing survival
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Table 4. Separate effects
3-Month graft
Description of kidney Frequency survival rates
Expected number of
grafts surviving at 3
months
Local 0 HLA-matches 20 0.7 14
1 35 0.8 28
35 0.9 31.5
Imported 0 HLA-matches 5 0.7 = 0.56
1 10 0.8 x 0.8 = 0.64
40 0.9 J = 0.72
2.8
6.4
28.8
Summary: Analysis of one covariate at a time
Covariate
Source Local 0.82a
Imported 0.69b
HLA-matching 0 0.67
0.76
0.80
a 2_14+28+3150.8
2.8 + 6.4 + 28.8b 0.69 = and so forth.
Table 5. Local versus imported kidney: No effect on graft survival
3-Month graft
Expected number of
grafts surviving at 3
Description of kidney Frequency survival rates months
Local 0 HLA-matches 20 0.7 14
1 35 0.8 28
35 0.9 31.5
Imported 0 HLA-matches 5 0.7 3.5
1 10 0.8 8
40 0.9 36
Summary: Analysis of one covariate at a time
Covariate
Source Local 0.82
Imported 0.86
HLA matching 0 0.7
1 0.8
0.9
data. The exponential and Weibull (for given shape parameter
c) models are special instances of proportional hazards. What is
proposed is that there is an underlying pattern of graft failure,
which we shall write as X0(t). Notice that the underlying hazard
X0(t) is not tied down as to the form it should take and certainly
may vary with the elapsed time since transplantation. In fact,
we allow the data to determine the form of X0(t). Continuing,
the proportional hazards model proposes that there is an
underlying pattern of graft failure and that this is acted on
multiplicatively by the covariates. The usual way in which these
assumptions are formulated is to write that the hazard at time t
for a patient with covariates Z = (Z1, Z2, Z3, Z4, Z5) is
X0(t)exp (/31Z1 + f32Z2 + /33Z3 + /34Z4 + /35Z5)
where f3, /32, ..., /3 (the weights given to individual covariates)
and X0(t) have to be estimated from the data. The sort of coding
for covariates which is typical is:
Z1 = recipient's age (in years) —40
Z2 = number of HLA-A and B matches
Z3 = 1 (imported kidney) or 0 (local kidney)
Z4 = number of transfusions given to the recipient
Z5 = 1 (multisystem disease present) or 0 (absent)
The expression X0(t) then describes the time-specific risk of
graft failure for a patient all of whose covariates are zero. The
patient is 40 years old and receives a local unmatched kidney,
has had no blood transfusion, and does not have multisysteni
disease. If the patient had been 50 years old instead of 40 and ii
13i had been estimated as 0.1, then the corresponding hazard
would always be 2.7 times greater being
X0(t) exp (0.1 x 10 + 0 + 0 + 0 + 0)
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Table 6. Interaction of effects
Description of kidney Frequency
3-Month graft
survival rates
Expected number of
grafts surviving at 3
months
Local 0 HLA-matches 20 0.7 14
1 35 0.8 282 35 0.9 31.5
Imported 0 HLA-matches 5 0.7 x 0.5 = 0.35 1.75
1 10 0.8 x 0.7 = 0.56 5.82 40 0.9 x 0.9 = 0.81 32.4
Summary: Analysis of one covariate at a time
Covariate
Source Local 0.82
Imported 0.73
HLA-matching 0 0.63
1 0.752 0.85
What characterizes the proportional hazards model is that
irrespective of the elapsed time since transplantation, the ratio
of the risks of graft failure in particular prognostic groups
remains constant, If, however, one covariate should violate the
proportional hazards assumption, then different underlying
hazard functions can be assumed in the strata defined by
appropriate levels of that particular covariate.
Two pointers that are a denial of proportional hazards, at
least in some disorders, are illustrated in Figure 3 (the Western
General breast cancer series). The first is the diversity of times
to maximum failure rate. Peak annual mortality in breast cancer
was not only greater but occurred earlier in stage 3 and stage 2
of the disease. The second denial of proportional hazards was
the relative unimportance in later follow-up of a description of
the tumor (International stage) that was relevant initially. By
the tenth year after diagnosis, the annual percentage dying is
similar for all three stages—remembering that a standard error
qualifies the estimates. In particular, survivors from stage 3
breast cancer seemed to experience the same rate of mortality
at 15 years after diagnosis as did survivors from stages 1 and 2.
The proportional hazards model would not be appropriate for
graft survival if, for example, the covariate first versus the
subsequent graft dictated when hyperacute rejection occurred
but uninformative about the likelihood of chronic rejection.
Further discussion of the time-dependent influence of covar-
iates is given in the next section.
The example of the Western General breast cancer series
leads to the last of four reference standards for analyzing
survival—the log-logistic distribution [4]. This has non-mono-
tone failure rate and accommodates diversity of times to peak
hazard and the ultimate convergence of failure rates for distinct
prognostic groups. One characterization of the log-logistic
model is that the hazard rates for two prognostic groups can be
transformed to proportionality by appropriately accelerating
the time scale of failures in one or the other group, hence, the
description of the log-logistic as one of a class of accelerated
failure time models.
The problem of fitting regression models to survival needs to
be referred to a statistician, but an initial assessment can be
made about what is an appropriate model by considering the
time-specific failure rates which have been estimated for the
series as a whole and according to covanates. In the Western
General breast cancer series example it is clear that the annual
proportion dying according to the International stage is neither
constant nor monotone (except perhaps for stage 4 disease) and
so neither the exponential nor the Weibull model should be
used. The proportional hazards model is not appropriate either,
because of divergence of times to peak hazard and the tendency
for the annual rates of mortality to coincide in later follow-up.
The log-logistic model would be a point of first reference
although even it does not adequately describe the data as they
happen.
Besides inspecting hazard plots as described above, there are
other graphical techniques tailored to particular distributions.
Two examples suffice. If the plot of the logarithm of the log
survivor function against the logarithm of time is a straight line
for each prognostic group and the straight lines have slope c,
then the Weibull model with the common shape parameter is
reasonable. The plausibility of the log-logistic model is checked
by plotting the log odds on death before time t against the
logarithm of time. There should result parallel straight lines for
each prognostic group, if the two parameter log-logistic distri-
bution is adequate.
The reader should consider again the pattern of graft failure
displayed in Table 1, that is, the decreasing risk with elapsed
time since transplantation, and take special notice of it. There is
not enough information available in the pattern for the series as
a whole to be certain about time-specific failure rates within
subgroups of the data. This is illustrated in the above example.
Annual mortality in the Western General breast cancer series as
a whole was decreasing (Fig. 2), a pattern which was not
inconsistent with non-monotone hazard according to Interna-
tional stage of the tumor.
I shall venture with two comments about graft survival, The
first is that constant hazard is unlikely, because even good
prognosis patients face an initial hurdle, that is, acute rejection.
The second concerns an observation in the 1981 United King-
dom Transplant Service Report where no significant correlation(r =
—0.29, P < 0.10) is recorded between a center's ranking
for graft failure rate in the first 3 months after transplantation
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and that in the subsequent period up to 24 months. One
interpretation is that the covariates which determine early and
late prognosis are different, there being, for example, distinct
prognostic indices for hyperacute and chronic rejection. An
alternative explanation is that some detail of treatment prolongs
function but does not influence the final outcome and so
detracts in the second interval from the performance of centers
which ranked highly in the first. None of the statistical models
which I have discussed so far copes very satisfactorily with
prognostic factors whose relevance is time-dependent. In the
next section I introduce a method for dealing with the possibili-
ty in an exploratory way.
Time-dependent relevance of covariates
An effective method by which to explore whether, and in
what way, the influence of covariates changes with time is, in
effect, a simple extension of the idea of proportional hazards.
Instead of estimating the constant of proportionality once (as
above), two or more separate time-intervals can be defined, and
we allow a constant of proportionality to be estimated in each.
This idea is related to Anderson and Senthilselvan's [8] two-
step regression model for hazard functions, but differs in so far
as their estimation of interval endpoints is perhaps an unneces-
sary refinement at an exploratory stage of analysis and adds to
computational difficulty. The above step function proportional
hazards technique can be represented as a formal statistical test
for nonproportional hazards, such as was discussed in Cox's
original article [1].
In a study of graft survival separate constants of proportion-
ality in two intervals, from transplantation to 90 days and from
90 days on, could be estimated. A patient whose graft was
rejected on day 140 would contribute a censored observation of
90 days to the first interval and an exact survival time of 50 days
to the second. If we write the constants of proportionality for
the first and second intervals of follow-up as
exp (a1Z1 + a2Z2 + a3Z3 + a4Z4 + a5Z5) first interval
exp (/31Z1 + l3zZ2 + /33Z3 + 134Z4 + /35Z) second interval
we can infer that the relevance of the covariate Z1 is time-
dependent if the estimated weights a1 and f3 are significantly
different. This type of informal significance testing should be
done only when the same background covariates Z2, Z3, Z4, Z5
have been fitted in both follow-up intervals. We are primarily
concerned with estimation. The step-function estimates a1, 13i
give an impression of how the effect of covariate Z1 changes
from one follow-up period to another. A clearer picture
emerges, of course, when more than two intervals are consid-
ered, but there is an important proviso, namely that there be
sufficient graft failures in each interval for efficient estimation of
the interval weights. If significance testing is one's goal, then,
of course, the logrank test can be applied in distinct follow-up
intervals and allowance made for other covariates in the usual
way; for example, review the United Kingdom Transplant
Service Annual Report for 1981 in which the intervals of
interest were from transplantation to 3 months and the subse-
quent period up to 24 months.
There is a certain arbitrariness in the above extension of the
proportional hazards model, through choice of the number of
distinct time-intervals (two in the example above) and their
lengths (see Anderson and Senthilselvan [81 for estimation of
interval endpoints). The two intervals selected are in keeping
with clinical interest, but there is no assurance that this is in any
statistical sense optimal. In an exploratory analysis this does
not matter particularly because with statistical advice interest-
ing results can lead to innovative modeling, such as exponential
decay in covariate effects, which is beyond the scope of this
introduction.
A second attribute of the above method is that it allows
prognostic information which evolves after transplantation to
modify the outlook for later follow-up. Thus, the covariate
Z6 = numberof treated rejection episodes in the first 60 days
may be introduced as a determinant of graft survival in the
second interval. The idea of regularly updating a patient's
prognosis is familiar ground to a doctor; only statisticians have
been slow to venture that way. Just as the patient's rehabilita-
tion status before transplant is a reasonable indicator of progno-
sis, so a measure which emerges in the early post-transplant
phase is a possible predictor of long-term outcome. Rehabilita-
tion status is mentioned again in the section on center by center
comparison.
The "center effect" on graft survival
The United Kingdom Transplant Service Report for 1981
confirms a wide discrepancy among renal units in respect of
graft survival up to 3 months and from 3 to 24 months post-
transplantation. This has become known as the "center effect",
that is, the center where a graft is inserted apparently influences
outcome (Fig. 6). The "center effect" on graft survival may be
artefact—explicable in terms of pre-transplant rehabilitation,
patient selection, HLA—matching, immunosuppression policy
and so forth—or, if real, may be more than one effect, being
time-dependent. Clearly, the center is a covariate, like any
other, and its true prognostic significance should be assessed
multifactorially, with the possibility of interaction with other
covariates kept in mind. Good statistical practice and the
lessons from Tables 4, 5, and 6 indicate that it is naive to
aggregate data across centers before analysis. Any logrank test
proposed should be performed on the data from individual
centers and the results, unless noticeably heterogeneous, then
pooled across centers. Correspondingly, in statistical modeling,
center effects must be taken account of and interaction terms
fitted if necessary.
The sections on survival data and data quality stressed the
importance of knowing how reliable are the data, and of giving
their general description, and are relevant to the study of center
effects. There is little point in making analysis more difficult
than necessary at the outset by including data from centers
whose records are not in good order. Moreover, to avoid
interaction between the year of transplantation and the effects
of other covariates, it is convenient at first to restrict attention
to patients who received a transplant in a recent year or years,
and to exclude centers at which few patients, for example less
than ten, were transplanted per annum. Morris [91 was more
radical still, restricting his report to six large United Kingdom
centers only. Later, of course, these restrictions can be relaxed,
so that the excluded strata (excluded by reason of year of
transplant, quality of data, and size of unit) can be brought into
the analysis. A general description of the data for each center
should include information about changes in center policy, in
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Fig. 4. Percent of survival in months. (Reproduced with permission
from [5].)
particular the date of any innovations.
More difficult to summarize is each patient's health or
rehabilitation status before transplantation. The 'center effect"
may be a proxy variable for high versus low risk patients. A
statistical or empirical index of health is needed which is simple
to compute for each patient, and reproducible when observers
from different centers assess the same patient. Humphrey et al
[10] reported an empirical score for predicting the risk of
peritonitis in individual patients about to begin continuous
ambulatory peritoneal dialysis. Crandon et al [11] found a
statistical index which predicted postoperative deep vein
thrombosis useful for deciding whether to give low-dose hepa-
rin pen-operatively. An index of health or rehabilitation status
before transplantation (which reflected the mental and physical
fitness of the patient and the urgency for receiving a graft)
would be worth having, not least because it might uncover
marked heterogeneity in the patients transplanted at different
centers.
What promise do regression models for graft survival hold
both generally and in terms of understanding the "center
effect"? First, they distinguish those covariates which are
related to graft survival in the important first 3 months from
those which influence what happens after 3 months. Differences
will be important. Some of the covariates may be patient
factors—age of the recipient, rehabilitation status, nature of
renal disease, and so forth. They help to identify the type of
patient who does well or badly. Other covariates may reflect
different center policies on immunosuppression or blood trans-
fusion. Questions about policy which are raised by such analy-
ses need to be answered in prospective randomized trials, as
discussed in the next section.
The second payoff is in terms of "center effects." These may
be eliminated because a sufficient explanation of the discrepan-
cies in graft survival has been given by the more obvious
covariates. If the center effects remain, there is an obvious need
to investigate whether the effects of other covariates are
consistent across centers. HLA matching could, for example,
be relevant only in units with a poor record for graft survival. In
centers which have good graft survival the number of HLA
matches might not matter much. Interactions may ultimately
hold the key to center effects; they were not investigated by
Morris [9].
The need for randomized controlled trials in renal units
Knapp [121 complained that the standards of evidence which
are tolerated in respect of treatments for renal failure are
inferior to those which regulate the introduction of new drug
treatments. Spodick et al [13] appealed to editors to consider an
explicit policy of equal standards for therapeutic trials of all
therapies and Chalmers [14] advanced ethical and scientific
reasons for randomization to begin with the first patient treated
by a new therapy.
The principle of randomization has been challenged for not
being expedient [15]. Randomized clinical trials impose disci-
pline on the selection and monitoring of patients, make ethical
consideration explicit and invite multicenter tribulation [16] if
the duration of study is to be limited. What has not been shown
is that the principle is ill-founded [17, 18] so that randomized
clinical trials remain the reliable method for making specific
comparisons between treatments [19].
Leaving aside altogether the issue of dialysis versus trans-
plantation—wherein lies potential trade-off between quantity
and quality of life—there is no shortage of specific questions to
be answered about the management of kidney transplant pa-
tients. Three such questions concern: (I) high versus low
immunosuppression regime, (2) timing of immunosuppression,
(3) value of HLA—matching. The priority that different trans-
plant teams and renal physicians give to the three questions will
not be the same; they might see other inquiries as more urgent.
What is needed is a complete list of specific questions, and a
survey to find out from transplant centers (1) how they rank
these questions in importance and (2) whether the center would
randomize patients in a clinical trial which addressed particular
questions. The advantages of the scheme would be to outline
the clinical and research value of specific questions and to
identify those units prepared to randomize patients in a collabo-
rative clinical trial. Centers which ranked at least one of the
above three questions highly, and whose policy was not so
committed on the other points as to bar randomization, would
be potential participants. Such centers could enter patients into
a factorially designed randomized trial. With this type of design,
the three questions are posed simultaneously, and each center
has the satisfaction of knowing that at least one of the hypothe-
ses is of special interest to it. If each of the factors—immuno-
suppression dose (high versus low), timing (scheme A or
scheme B), and HLA matching (unrestricted versus two or
more matches)—is compared at two levels, as shown, then
there are 2 x 2 x 2 = 8 treatment combinations. In a factorial
design, with equal randomization, half of the patients receive
high dose immunosuppression, half low dose (Fig. 5) and
similarly for the other factors. The design is efficient and is very
suitable for use in multicenter collaborative trials in the man-
agement of kidney transplant patients.
To be successful trials must ask relevant questions. Factorial
designs are recommended because several problems are re-
solved with the same investment of resources (patients, time,
and effort) as would have been needed to answer only one of
them.
Conclusion
There has been a steady improvement in graft survival
without the reasons for it having been established. Retrospec-
tive analysis of graft survival by the multifactorial methods
Time, months
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Fig. 5. Factorial design—treatment allocation.
outlined in this paper can identify prognostic factors and may
also be used to explore the "center effect" on graft survival.
The relevance of covariates may be time-dependent. Discrepan-
cies in graft survival between centers may be explained in terms
of patients' rehabilitation before transplantation and a scoring
system would be useful.
Retrospective analysis should not be taken to indict or
promote any treatment policy; only randomized comparisons
avoid the biases inherent in selecting historical controls and
give sufficiently reliable evidence about small treatment bene-
fits. A survey of renal units to elicit research priorities is
proposed. Factorial designs are recommended as an efficient
way of investigating several specific questions. Multicenter
collaboration would ensure that answers were speedily
available.
Summary
Simple life-table analyses have not identified the reasons for
the steady improvement over the years in graft survival. The
use of more sophisticated multifactorial statistical techniques is
indicated to identify prognostic factors and to explore the
"center effect" on graft survival.
An agenda for retrospective analysis of graft survival is
proposed as follows. The first item is organizing and checking
both survival and covariate data to provide a general descrip-
tion of the transplant series so that one knows, for example,
which covariates are interdependent. Plotting lifetables and the
time-specific risk of graft failure for one covariate at a time is
the next step. The limitations of such analyses are easy to
demonstrate and are illustrated with examples which motivate a
multifactorial approach. Standard regression models for surviv-
al data, such as the exponential, Weibull, proportional hazards,
and log-logistic, are described with the caveat that in medical
applications, particularly the relevance of covariates, may be
time-dependent, not constant on a particular scale (hazard or
log odds). The method which is described for exploring how the
relevance of covariates changes with elapsed time since trans-
plantation is a simple step-function extension of the idea of
proportional hazards.
Because discrepancies in graft survival between centers, the
"center effect," may owe something to the patient's rehabilita-
tion before transplantation, a scoring system for rehabilitation
or performance status would be useful as a summary covariate.
Even careful retrospective analysis will not usually promote
or indict a treatment policy without confirmation from random-
ized comparisons. A survey of renal units to elicit research
priorities is suggested and factorial designs are recommended as
an efficient way of investigating several specific questions.
Multicenter collaboration in clinical trials would ensure that
answers were speedily available.
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